For patients with ESR1-mutated, hormone receptor (HR)-positive, HER2-low metastatic breast cancer, progression on initial CDK4/6 inhibitor-based therapy presents a key sequencing decision. Claudine Isaacs, MD, professor of medicine and oncology,…
Category: 6. Business
-
Pinsent Masons completes move into new Sydney office
The firm has moved into levels 16 and 17 of 33 Alfred St today, occupying 2,600 square metres of office space – an increase of 1,850 square metres from its previous home at 1 Macquarie Place.
The heritage-listed building – Sydney’s…
Continue Reading
-
Fostering Resiliency in Mental Health Professionals: A Strengths-Based, Trauma-Informed Framework
Resilience is commonly defined as the capacity to recover from difficulties and adapt positively in the face of adversity.1 For mental health professionals, resilience refers to not only “bouncing back,” but also adaptive and flexible ways…
Continue Reading
-
Allison Transmission 4500 RDS Model Now Pairs with Cummins X15N Natural Gas Engine, Delivering Enhanced Performance and Efficiency
INDIANAPOLIS, Oct. 6, 2025 /PRNewswire/ — Allison Transmission is proud to announce its 4500 Rugged Duty Series (RDS) fully automatic transmission has been successfully integrated with the Cummins X15N natural gas…
Continue Reading
-
Retrospective Study Shows BTK Inhibitors Provide PFS Advantage in NOTCH1-Mutated CLL
Treatment with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) harboring NOTCH1 mutations was associated with significantly longer progression-free survival (PFS) compared with chemoimmunotherapy, according to findings from a…
Continue Reading
-
Dato-DXd Shows Promise as First-Line Therapy in Metastatic TNBC | Pharmacy Times
A new study shows datopotamab deruxtecan (Dato-DXd; Datroway; AstraZeneca) offers a meaningful survival advantage in a subgroup of patients with metastatic triple-negative breast cancer (mTNBC) who are not eligible for immunotherapy, according to…
Continue Reading
-
September 2025 Monthly Rewind: Key News and Expert Insights You May Have Missed in Lung Cancer
September brought a series of pivotal updates in non–small cell lung cancer (NSCLC) treatment, including FDA regulatory decisions, late-breaking clinical trial results, and expert insights from the 2025
International Association for the Study… Continue Reading
-
‘Couldn’t pronounce Nvidia’ until 8 months ago
Legendary investor Peter Lynch built a reputation for routinely beating the market while overseeing Fidelity Magellan Fund in the 1980s. Decades later, he has some advice for the next generation of investors.
The artificial intelligence boom has…
Continue Reading
-
Poll: Vote on the Top Gynecologic and GI Cancer Abstracts/Topics to Watch at ESMO 2025
As the
2025 ESMO Congress in Berlin continues to inch closer, the excitement ahead of the meeting’s first sessions on October 17 continues to build. Late-breaking abstracts (LBAs) are again set to potentially impact clinical practice, and…Continue Reading
